Active Ingredient History
Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 1/Phase 2)
Adrenal Gland Neoplasms (Phase 2)
Anemia (Phase 1)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
Breast Diseases (Phase 1/Phase 2)
Breast Neoplasms, Male (Phase 1)
Carcinoid Tumor (Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Squamous Cell (Early Phase 1)
Cholangiocarcinoma (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 2)
Endometrial Neoplasms (Phase 2)
Epidermal Growth Factor (Phase 2)
ErbB Receptors (Phase 2)
Esophageal Neoplasms (Phase 2/Phase 3)
Fallopian Tube Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Genes, erbB-2 (Phase 1)
Glioma (Phase 2)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 2)
Hemangiosarcoma (Phase 2)
Hodgkin Disease (Phase 1)
Hypertrophy, Left Ventricular (Phase 2)
Inflammatory Breast Neoplasms (Phase 3)
Kidney Neoplasms (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Melanoma (Phase 2)
Meninges (Phase 1/Phase 2)
Multiple Endocrine Neoplasia (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 1)
Myeloproliferative Disorders (Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Neoplastic Cells, Circulating (Phase 2)
Neuroblastoma (Phase 2)
Neuroendocrine Tumors (Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 2)
Primary Myelofibrosis (Phase 1)
Progression-Free Survival (Phase 2)
Prostatic Neoplasms (Phase 2)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 3)
Thyroid Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
